Preferred practice patternDry Eye Syndrome Preferred Practice Pattern®
Section snippets
CORNEA/EXTERNAL DISEASE PREFERRED PRACTICE PATTERN® DEVELOPMENT PROCESS AND PARTICIPANTS
The Cornea/External Disease Preferred Practice Pattern® Panel members wrote the Dry Eye Syndrome Preferred Practice Pattern® guidelines (PPP). The PPP Panel members discussed and reviewed successive drafts of the document, meeting in person twice and conducting other review by e-mail discussion, to develop a consensus over the final version of the document.
Cornea/External Disease Preferred Practice Pattern Panel 2017–2018
Esen K. Akpek, MD
Guillermo Amescua, MD
Marjan Farid, MD
Francisco J.
FINANCIAL DISCLOSURES
In compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies (available at www.cmss.org/codeforinteractions.aspx), relevant relationships with industry are listed. The Academy has Relationship with Industry Procedures to comply with the Code (available at www.aao.org/about-preferred-practice-patterns). A majority (70%) of the members of the Cornea/External Disease Preferred Practice Pattern Panel 2017–2018 had no financial relationships to disclose.
TABLE OF CONTENTS
OBJECTIVES OF PREFERRED PRACTICE PATTERN GUIDELINES P291
METHODS AND KEY TO RATINGS P292
HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE P293
INTRODUCTION P294
Disease Definition P294
Patient Population P294
Clinical Objectives P294
BACKGROUND P294
Prevalence and Risk Factors P294
Pathogenesis P296
Associated Conditions P297
Natural History P299
CARE PROCESS P299
Patient Outcome Criteria P299
Diagnosis P299
History P301
Examination P302
Diagnostic Tests P303
Classification of Dry Eye Syndrome P306
Management
OBJECTIVES OF PREFERRED PRACTICE PATTERN® GUIDELINES
As a service to its members and the public, the American Academy of Ophthalmology has developed a series of Preferred Practice Pattern® guidelines that identify characteristics and components of quality eye care. Appendix 1 describes the core criteria of quality eye care.
The Preferred Practice Pattern® guidelines are based on the best available scientific data as interpreted by panels of knowledgeable health professionals. In some instances, such as when results of carefully conducted clinical
METHODS AND KEY TO RATINGS
Preferred Practice Pattern® guidelines should be clinically relevant and specific enough to provide useful information to practitioners. Where evidence exists to support a recommendation for care, the recommendation should be given an explicit rating that shows the strength of evidence. To accomplish these aims, methods from the Scottish Intercollegiate Guideline Network1 (SIGN) and the Grading of Recommendations Assessment, Development and Evaluation2 (GRADE) group are used. GRADE is a
HIGHLIGHTED FINDINGS AND RECOMMENDATIONS FOR CARE
Dry eye is a common ocular condition that has a substantial impact on the quality of life of afflicted individuals owing to discomfort and visual disability. Dry eye may compromise results of corneal, cataract, and refractive surgery.
No single test is adequate for establishing the diagnosis of dry eye. The constellation of findings from multiple tests can add greatly to the clinician's understanding of the patient's condition.
Pharmacological and procedural treatments are associated with
DISEASE DEFINITION
Dry eye disease (also known as dry eye syndrome) refers to a group of disorders of the tear film that are due to reduced tear production or tear film instability, associated with ocular discomfort and/or visual symptoms and inflammatory disease of the ocular surface.
PATIENT POPULATION
The patient population includes individuals of all ages who present with symptoms and signs suggestive of dry eye, such as ocular irritation, redness, mucus discharge, fluctuating vision, and decreased tear meniscus or plugged
BACKGROUND
Dry eye, either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads patients to seek ophthalmologic care.15 Even though these symptoms often improve with treatment, the disease usually is not curable, which may be a source of patient and physician frustration. Importantly, dry eye is also a cause of reduced visual function16, 17, 18, 19 and may compromise results of corneal, cataract, and refractive surgery.
PATIENT OUTCOME CRITERIA
Outcome criteria for treating dry eye include the following:
- ♦
Reduce or alleviate signs and symptoms of dry eye, such as ocular irritation, redness, or mucous discharge
- ♦
Maintain or improve visual function
- ♦
Reduce or prevent ocular surface damage
DIAGNOSIS
Many ocular surface diseases produce symptoms that are similar to those associated with dry eye, including foreign body sensation, mild itching, irritation, and soreness. Identifying characteristics of the causative factors, such as adverse
APPENDIX 1. QUALITY OF OPHTHALMIC CARE CORE CRITERIA
Providing quality care is the physician's foremost ethical obligation, and is the basis of public trust in physicians.
AMA Board of Trustees, 1986
Quality ophthalmic care is provided in a manner and with the skill that is consistent with the best interests of the patient. The discussion that follows characterizes the core elements of such care.
The ophthalmologist is first and foremost a physician. As such, the ophthalmologist demonstrates compassion and concern for the individual, and utilizes
APPENDIX 2. INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS (ICD) CODES
Dry eye includes entities with the following ICD-10 classifications:
CM = Clinical Modification used in the United States; ICD = International Classification ofICD-10 CM Dry eye, unspecified, right lacrimal gland H04.121 Dry eye, unspecified, left lacrimal gland H04.122 Dry eye, unspecified, bilateral lacrimal gland H04.123 Dry eye, keratoconjunctivitis sicca (not specified as Sjögren) H16.22- Dry eye, Sjögren syndrome, Sicca syndrome M35.00 Dry eye, Sjögren syndrome, with keratoconjunctivitis M35.01
APPENDIX 3. SJÖGREN SYNDROME
Sjögren syndrome is defined as dry eye and dry mouth associated with systemic immune dysfunction. About 10% of patients with clinically significant dry eye have an underlying Sj□gren syndrome.57, 58 A significant proportion of the patients may not have been diagnosed at the time they present to the ophthalmology clinic with dry eye complaints.
Sj□gren syndrome is characterized by infiltration of the lacrimal and salivary glands with lymphocytes with secondary compromise of gland function.
APPENDIX 4. DIAGNOSTIC TESTS
This appendix summarizes the applicability of currently utilized tests to diagnose tear film and ocular surface disorders. These tests include the tear break-up time test to evaluate tear film stability, ocular surface dye staining to evaluate ocular surface disease, the Schirmer test and fluorescein disappearance test to evaluate aqueous tear production and clearance, and the tear osmolarity test.
LITERATURE SEARCHES FOR THIS PPP
Literature searches of the PubMed and Cochrane databases were conducted in March 2017; the search strategies were as follows. Specific limited update searches were conducted after June 2018.
Dry Eye Syndrome:
(“dry eye syndromes”[MeSH Terms] OR dry eye[tiab])
Epidemiology:
(“dry eye syndromes/epidemiology”[majr:noexp]) OR (“dry eye syndromes/ethnology”[majr:noexp]) OR ((dry eye[tiab) AND (prevalence[tiab] OR epidemiolog*[tiab] OR ethn*[tiab]))
Etiology:
(“dry eye syndromes/etiology”[majr:noexp]) OR
RELATED ACADEMY MATERIALS
Basic and Clinical Science Course
External Disease and Cornea (Section 8, 2018–2019)
Patient Education Brochure
Dry Eye (2014)
Spanish Language Brochure: Ojo Seco (2014)
Preferred Practice Pattern® Guidelines – Free download available at www.aao.org/ppp.
Comprehensive Adult Medical Eye Evaluation (2015)
Pediatric Eye Evaluations (2017)
REFERENCES (203)
- et al.
Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment
Ophthalmology
(2007) - et al.
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study
Ophthalmology
(2014) - et al.
Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)
Ophthalmology
(2017) - et al.
Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study
Ophthalmology
(2015) - et al.
Dissatisfaction after multifocal intraocular lens implantation
J Cataract Refract Surg
(2009) - et al.
Prevalence of dry eye among the elderly
Am J Ophthalmol
(1997) - et al.
The epidemiology of dry eye in Melbourne, Australia
Ophthalmology
(1998) - et al.
Prevalence of dry eye syndrome among US women
Am J Ophthalmol
(2003) - et al.
Prevalence of treated dry eye disease in a managed care population
Clin Ther
(2001) - et al.
Prevalence of dry eye disease among Japanese visual display terminal users
Ophthalmology
(2008)